ScoreWhy is Beryl Drugs Ltd ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 10.21% and Operating profit at 5.06% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.75
2
Flat results in Dec 25
- NET SALES(9M) At Rs 13.84 cr has Grown at -20.14%
- PBDIT(Q) Lowest at Rs -0.20 cr.
- PBT LESS OI(Q) Lowest at Rs -0.61 cr.
3
Stock is technically in a Bearish range
- The technical trend has deteriorated from Mildly Bearish on 20-May-26 and has generated -5.42% returns since then
- Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
4
Below par performance in long term as well as near term
- Along with generating -2.51% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Beryl Drugs for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Beryl Drugs
12.34%
-0.04
63.75%
Sensex
-11.8%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.33%
EBIT Growth (5y)
5.39%
EBIT to Interest (avg)
0.92
Debt to EBITDA (avg)
2.51
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
1.58
Tax Ratio
20.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.35%
ROE (avg)
5.66%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
21
Industry P/E
36
Price to Book Value
1.30
EV to EBIT
13.61
EV to EBITDA
5.92
EV to Capital Employed
1.24
EV to Sales
0.68
PEG Ratio
0.12
Dividend Yield
NA
ROCE (Latest)
7.63%
ROE (Latest)
6.28%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
NET SALES(Latest six months)
At Rs 13.04 cr has Grown at 29.75%
PAT(Latest six months)
Higher at Rs 0.78 cr
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Beryl Drugs
Net Sales - Latest six months
At Rs 13.04 cr has Grown at 29.75%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
Higher at Rs 0.78 cr
than preceding 12 month period ended Jun 2026 of Rs 0.01 crMOJO Watch
In the half year the company has already crossed PAT of the previous twelve months
PAT (Rs Cr)
